No Picture

New analysis shows inclisiran consistency in LDL-C reduction as Novartis readies for FDA decision

As the FDA continues its review of the former-The Medicines Company, now-Novartis candidate inclisiran ahead of an expected PDUFA before the year is out, the Swiss pharma released pooled data that it hopes bolsters the case for approval.
A post-hoc ana… […]